Načítá se...
Novel oral anticoagulants for atrial fibrillation
Anticoagulation therapy is effective in preventing primary and secondary thromboembolic events due to atrial fibrillation. Warfarin, which was approved by the United States in 1954, was the only long-term oral anticoagulation therapy till the approval of dabigatran in 2010, and of rivaroxaban and ot...
Uloženo v:
| Vydáno v: | Singapore Med J |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Singapore Medical Association
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4678403/ https://ncbi.nlm.nih.gov/pubmed/26702159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.11622/smedj.2015184 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|